Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson(Harvard University), Yen Charles, Fevzi Altuntaş, Carlos Arce‐Lara, Paweł Robak(Medical University of Lodz), Darrell White(Dalhousie University), Pekka Anttila, Nicola Cascavilla, Jesús F. San Miguel(Clinica Universidad de Navarra), Katja Weisel(Universität Hamburg), Steve Schey(King's College London), Thierry Façon(Université de Lille), Kenneth Anderson(Harvard University), Olga Meltem Akay, Joan Bladé(Hospital Clínic de Barcelona), Mohamed H. Zaki, Meletios Α. Dimopoulos(Korea University), Lillian Burke, Larry D. Anderson(Dana-Farber Cancer Institute), Tsvetan Biyukov(Bristol-Myers Squibb (Switzerland)), Kazutaka Sunami(National Hospital Organization), Peter O’Gorman(University College Dublin), Bipinkumar Amin(Bristol-Myers Squibb (Switzerland)), С. В. Семочкин(Pirogov Russian National Research Medical University), Amine Bensmaine(Bristol-Myers Squibb (Switzerland)), Albert Oriol(Institut Català d'Oncologia), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Niels Abildgaard(University of Southern Denmark), Peter D. Byeff(University College Dublin), Lotfi Benboubker, Anna Marina Liberati(University of Perugia), Andrew Chantry(University of Sheffield), Michèle Cavo(Unknown), Jindriska Lindsay(East Kent Hospitals University NHS Foundation Trust), Fredrik Schjesvold(Oslo University Hospital), Mónica Galli(Ospedale Papa Giovanni XXIII), Meral Beksaç(Liv Hospital), Thomas Doerr(Bristol-Myers Squibb (United States)), Xin Yu(National Institutes of Health), Supratik Basu, Yıldız Aydın, Carla Araujo, Dina Ben‐Yehuda(Hebrew University of Jerusalem), Ramakrishna Battini, Howard L. Adler, Ralph V. Boccia, Teresa Peluso(Bristol-Myers Squibb (Switzerland)), Thaddeus Beeker, Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 383
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k